Impaired folate status in patients with mental disorders
Acta Neuropsychiatrica · 2025
DOI: 10.1017/neu.2025.1 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Neuropsychiatrica, 2025. Verfasst von Narvini Rajen und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Biochemistry and Pharmacology, Haukeland University Hospital, Bergen, Norway. Hauptthemen laut MEDLINE: Mental Disorders, Folic Acid, Folic Acid Deficiency, Vitamin B 12. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
Folate and cobalamin deficiency or impaired function due to genetic variants in key enzymes have been associated with neuropsychiatric symptoms. The aim of this study was to compare folate and cobalamin status in patients admitted to an acute psychiatric unit to patients from primary health care in order to reveal factors which may be important in the follow-up of patients with mental disorders.
Methods
Anonymous blood samples tested for folate, cobalamin, the metabolic marker total homocysteine (tHcy), creatinine and glomerular filtration rate as well as age and gender in patients admitted to a psychiatric acute unit ( n = 981) and patients from primary health care (controls) ( n = 32,201) were reviewed retrospectively.
Results
Median serum folate was 18% lower and median serum cobalamin was 11% higher in patients with mental disorders compared to controls. Folate deficiency was associated with 54% higher median tHcy levels among patients with mental disorders compared to controls. The prevalence of folate deficiency was 31% and of cobalamin deficiency 6% in patients admitted to a psychiatric acute unit in a Norwegian hospital in 2024.
Conclusion
Folate, but not cobalamin deficiency, was prevalent in Norwegian patients with mental disorders. The higher tHcy levels in folate-deficient patients with mental disorders indicate an impaired folate metabolism, which might be related to genetic factors, such as polymorphisms in the methylenetetrahydrofolate reductase (MTHFR) gene. Ensuring a serum folate concentration above 15 nmol/L and a serum cobalamin above 250 pmol/L might improve symptoms in patients with mental disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Biochemistry and Pharmacology, Haukeland University Hospital, Bergen, Norway.
- Division of Psychiatry, Haukeland University Hospital, Bergen, Norway.
- Department of Clinical Medicine, University of Bergen, Bergen, Norway.
- Mohn Research Center for Psychotic Disorders, Bergen, Norway.
- Laboratory of Medical Biochemistry, Innlandet Hospital Trust, Lillehammer, Norway.
- Laboratory of Medical Biochemistry, Førde Hospital Trust, Førde, Norway.
ORCID-Profile: Anne-Lise Bjørke-Monsen
Zitieren
APA
Rajen, N., Velure, H. W., Johnsen, E., & Bjørke-Monsen, A. L. (2025). Impaired folate status in patients with mental disorders. Acta Neuropsychiatrica. https://doi.org/10.1017/neu.2025.1
Vancouver
Rajen N, Velure HW, Johnsen E, Bjørke-Monsen AL. Impaired folate status in patients with mental disorders. Acta Neuropsychiatrica. 2025. doi:10.1017/neu.2025.1
BibTeX
@article{Rajen2025,
author = {Rajen, Narvini and Velure, Hanne Wrengler and Johnsen, Erik and Bjørke-Monsen, Anne-Lise},
title = {Impaired folate status in patients with mental disorders},
journal = {Acta Neuropsychiatrica},
year = {2025},
doi = {10.1017/neu.2025.1}
}
EUVIMED